Results 101 to 110 of about 8,760 (175)
Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease
Background Pyoderma gangrenosum is a serious cutaneous complication seen in approximately 1 % of patients with inflammatory bowel disease (IBD). Oral corticosteroids are the mainstay treatment, although the evidence supporting their use is weak.
Garcia-Sanchez, V. +16 more
core +1 more source
Therapy Insight: pyoderma gangrenosum-old disease, new management.
Well-designed studies that help guide physicians to apply the optimal therapeutic strategy for the management of pyoderma gangrenosum are lacking in the literature. A multidisciplinary approach is paramount for the effective management of this condition,
Jewell, DP +5 more
core +1 more source
Περιγράφεται περίπτωση γαγγραινώδους πυοδέρματος, μιας δερματοπάθειας που χαρακτηρίζεται από χρόνια υποτροπιάζοντα έλκη με συνύπαρξη βλαβών αγγειίτιδας.
ΑΝΔΡΟΥΛΑΚΗΣ, Ι. +2 more
core
Superficial Granulomatous Pyoderma
Superficial granulomatous pyoderma is an uncommon, benign, superficial variant of pyoderma gangrenosum, having granulomatous histological features and no systemic association. We describe 6 Indian patients with superficial granulomatous pyoderma.
Sarkar Rashmi +3 more
doaj
A challenging diagnosis: case report of extensive pyoderma gangrenosum at multiple sites
Mingwei J Ye,1,2 Joshua Mingsheng Ye,2 Leonard Wu,3 Cameron P Keating,4 Wai-Ting Choi41Department of Dermatology, Western Hospital, Footscray, VIC, Australia; 2University of Melbourne, Department of Medicine, Dentistry and Health Sciences, Parkville, VIC,
Ye JM, Wu L, Ye MJ, Keating CP, Choi WT
core
Pyoderma Gangrenosum of the Eyelid: A Challenging Case. [PDF]
AlAbdullah ZA +3 more
europepmc +1 more source
Case Study of Fulminant Pyoderma Gangrenosum: Conservative Therapy-Cornerstone of Management. [PDF]
Yuen JC, Schneck JW, Shalin SC.
europepmc +1 more source
Bimekizumab for recalcitrant pyoderma gangrenosum. [PDF]
Tolete C +3 more
europepmc +1 more source
Pyoderma gangrenosum following treatment with azacitidine in a patient with myelodysplastic syndrome. [PDF]
Dubakula V, Fort C, Pham C, Dubin M.
europepmc +1 more source

